Antineoplastic Chemotherapics Platinum-Based Under the Light of Evolutionary Biology

Abstract

The platinum-based coordination compounds consist of an important class of antineoplastic chemotherapeutics with a view to their worldwide commercialization. Even cisplatin being officially approved in 1978 by the FDA, Cairns (in 1975) and Nowell (1976) had already postulated the emergence of drug-resistant tumor cells via somatic evolution; i.e., the need for reflection on Darwinian dynamics was already known. The evolutionary adaptations of cancer must be known in order to avoid the arise of the multidrug resistance phenomenon (MDR), whose phenotypic expressions may include processes such as angiogenesis, inflammatory lesions, oxidative metabolism and ultra-expression of telomerase, acquired during the stages of carcinogenesis. In this paper, we discuss the platinum composition and a view of evolutionary biology in the design of new platinum-drugs antineoplastic influenced by what we call of the "Bait-Hook principle".

Obtenção de complexos de Pt(II) e Pd(II) derivados de 1,3,4-oxadiazol-2-(3H)-tiona e 5-amino-1,3,4-tiadiazol-2-tiol: potencial antitumoral de dois complexos de Pt(II) contendo 1,10-fenantrolina

“…Vera LúciaDe et al, 2005;BELIAN, 2018;FAGUET, 2015). Compostos organometálicos à base de arsênio estudados por Paul Ehrlich.Com a descoberta dos raios-X em por Wilhelm Conrad Roentgen da Alemanha, bem como as contribuições de Marie Curie nas pesquisas relacionadas à radiação, a radioterapia se tornou um complemento na luta contra o câncer (BASKAR et al, 2012)…”